Posted by
Intranasal esketamine combo tied to symptom improvement

Intranasal esketamine combo tied to symptom improvement

Concern raised about drug’s abuse potential Publish date: May 21, 2019 By Jim Kling REPORTING FROM APA 2019 SAN FRANCISCO – In treatment-resistant depression, a switch to a new antidepressant combined with inhaled esketamine (Spravato) led to better symptom improvement than did a switch to a new antidepressant plus placebo, results from a new trial show. The […]

Posted by
In scathing ruling, judge rips insurer for putting ‘bottom line’ over patients’ health

In scathing ruling, judge rips insurer for putting ‘bottom line’ over patients’ health

In a scathing decision, a federal judge blasted a subsidiary of the nation’s largest insurance company for focusing on the “bottom line as much or more” than patients’ health, saying the insurer illegally denied treatment to thousands of people. The judge also slammed the company’s medical directors for being “deceptive” under oath.US Chief Magistrate Judge […]

Posted by
FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic

FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic

For Immediate Release March 5, 2019 Release The U.S. Food and Drug Administration today approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them (treatment-resistant depression). Because of the risk of serious adverse outcomes resulting […]

Posted by
FDA Clears 3-Minute Brain Stimulation Protocol for Depression

FDA Clears 3-Minute Brain Stimulation Protocol for Depression

The US Food and Drug Administration (FDA) has approved a newer and faster treatment protocol for the MagVita repetitive transcranial magnetic stimulation (rTMS) therapy system from MagVenture, the company has announced. The FDA first cleared the MagVitaTMS therapy system in 2015 for treatment of adults with drug-resistant major depressive disorder, as reported by Medscape Medical News. Until now, each treatment […]